Revolution COO sells 10K shares after option exercise
Revolution Medicines, Inc. reported insider activity by Chief Operating Officer Margaret A. Horn.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. reported insider activity by Chief Operating Officer Margaret A. Horn. On June 11, 2026, she exercised stock options to acquire a total of 10,000 shares of common stock at exercise prices of $40.74 and $42.45 per share. The same day, she sold 10,000 shares of common stock in open-market transactions at prices ranging from $143.78 to $150.15 per share. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating a planned exercise-and-sell pattern rather than ad hoc trading.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($1.07M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Horn Margaret A
Role
Chief Operating Officer
Sold
10,000 shs ($1.48M)
Approx. gross sale proceeds
$1.48M
Approx. exercise cost
$409K
Approx. pre-tax spread
$1.07M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,094 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 8,906 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,094 | $42.45 | $46K |
| Exercise | Common Stock | 8,906 | $40.74 | $363K |
| Sale | Common Stock | 1,315 | $144.2793 | $190K |
| Sale | Common Stock | 885 | $145.1495 | $128K |
| Sale | Common Stock | 700 | $146.0371 | $102K |
| Sale | Common Stock | 500 | $147.272 | $74K |
| Sale | Common Stock | 1,800 | $148.7231 | $268K |
| Sale | Common Stock | 4,600 | $149.6429 | $688K |
| Sale | Common Stock | 200 | $150.17 | $30K |
Holdings After Transaction:
Stock Option (Right to Buy) — 91,194 contracts (Direct);
Common Stock — 158,222 shares (Direct)
Footnotes (10)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
- F2. Includes 73,050 restricted stock units.
- F3. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
- F4. This transaction was executed in multiple trades in prices ranging from $143.78 to $144.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. This transaction was executed in multiple trades in prices ranging from $144.79 to $145.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. This transaction was executed in multiple trades in prices ranging from $145.88 to $146.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. This transaction was executed in multiple trades in prices ranging from $147.06 to $147.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8. This transaction was executed in multiple trades in prices ranging from $148.14 to $149.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9. This transaction was executed in multiple trades in prices ranging from $149.17 to $150.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F10. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Shares sold: 10,000 shares
Shares exercised: 10,000 shares
Exercise price 1: $40.74/share
+4 more
7 metrics
Shares sold
10,000 shares
Open-market sales on June 11, 2026
Shares exercised
10,000 shares
Stock option exercises on June 11, 2026
Exercise price 1
$40.74/share
Stock option exercise price
Exercise price 2
$42.45/share
Stock option exercise price
Sale price range
$143.78–$150.15/share
Prices for multiple sale trades
RSUs included
73,050 units
Restricted stock units included in holdings
ESPP shares
652 shares
Acquired under Employee Stock Purchase Plan
Key Terms
Rule 10b5-1 trading plan, restricted stock units, Employee Stock Purchase Plan, Stock Option (Right to Buy), +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 73,050 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Purchase Plan financial
"Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (Right to Buy) financial
"Security title listed as Stock Option (Right to Buy) with underlying common stock."
derivative exercise/conversion financial
"Transaction action is described as derivative exercise/conversion for code M entries."
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates